SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Portfolio Pulse from
Faruqi & Faruqi, LLP is investigating potential securities law violations by Intellia Therapeutics related to its Phase 1/2 study for NTLA-3001. The law firm alleges that the company made false or misleading statements about its clinical timeline and failed to disclose declining interest in viral-based editing. On January 9, 2025, Intellia announced it would discontinue NTLA-3001, cut 27% of its workforce, and incur $8 million in restructuring charges, causing its stock to drop 15.14%.
April 10, 2025 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Potential securities class action lawsuit alleges company misled investors about NTLA-3001 study and market conditions, leading to stock price decline
The lawsuit alleges material misrepresentations about the company's clinical study and technology, which could negatively impact investor confidence and stock performance
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100